The stock edged up 1.7% post-earnings, reflecting a broadly in-line performance with mixed signals from pricing pressure in key segments partially offset by strong underwriting results and cost efficiency initiatives.
- Net income of USD 2.8 billion in H1 represents over 60% of the full-year target of USD 4.5 billion, signaling solid progress but not a clear acceleration.
- Life & Health Re showed stable in-force margins and positive experience, particularly in U.S. mortality, supporting confidence in the USD 1.7 billion 2026 target.
- P&C Re posted strong underwriting results with low natural catastrophe losses (USD 676 million below expectations) and significant reserve releases, though pricing remains challenged with high-single-digit declines in nonproportional property.
- Midyear renewals indicated volume growth of 11% but nominal pricing was broadly flat to down mid-single-digit in certain portfolios, highlighting ongoing competitive pressures and cycle management challenges.
- Operating cost reduction target was raised to USD 500 million by 2028, reflecting strong early progress and ongoing efficiency efforts, signaling management's focus on structural cost control amid margin headwinds.
Community Discussion